Apricus Biosciences Company Profile (NASDAQ:APRI)

About Apricus Biosciences

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: APRI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.34
  • 50 Day Moving Average: $0.345
  • 200 Day Moving Average: $0.472
  • 52-Week Range: $0.28 - $1.68
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.90
  • P/E Growth: 0.000
  • Market Cap: $22.89M
  • Outstanding Shares: 66,350,000
  • Beta: 0.64
Profitability:
  • Net Margins: -265.51%
  • Return on Assets: -173.64%
Debt:
  • Current Ratio: 0.37%
  • Quick Ratio: 0.31%
Additional Links:
Companies Related to Apricus Biosciences:

Analyst Ratings

Consensus Ratings for Apricus Biosciences (NASDAQ:APRI) (?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $2.23 (544.93% upside)

Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI)
Show:
DateFirmActionRatingPrice TargetDetails
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95View Rating Details
3/11/2016Dawson JamesReiterated RatingBuyView Rating Details
12/9/2015Sterne Agee CRTDowngradeBuy -> NeutralView Rating Details
11/6/2015Roth CapitalDowngradeBuy -> Neutral$1.50View Rating Details
8/13/2015Ascendiant Capital MarketsInitiated CoverageBuy$2.50View Rating Details
10/28/2014Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Apricus Biosciences (NASDAQ:APRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q216($0.08)($0.05)$1.52 millionViewListenView Earnings Details
5/9/2016Q116($0.09)($0.09)ViewN/AView Earnings Details
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details
8/5/2015Q2($0.13)($0.10)ViewListenView Earnings Details
5/11/2015Q1($0.10)($0.13)ViewListenView Earnings Details
3/16/2015Q4($0.12)($0.09)$1.90 millionViewListenView Earnings Details
11/10/2014Q314($0.10)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details
8/12/2014Q214($0.04)$0.05$5.45 million$5.50 millionViewN/AView Earnings Details
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
Current Year EPS Consensus Estimate: $-0.170 EPS
Next Year EPS Consensus Estimate: $-0.050 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.09)($0.08)($0.09)
Q2 20162($0.10)($0.06)($0.08)
Q3 20162($0.08)($0.07)($0.08)
Q4 20162($0.05)($0.03)($0.04)
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Apricus Biosciences (NASDAQ:APRI)
Insider Ownership Percentage: 3.21%
Institutional Ownership Percentage: 26.95%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Apricus Biosciences (NASDAQ:APRI)
DateHeadline
News IconPenny Stock Investors are Growing Curious About Apricus Biosciences, Inc. (NASDAQ:APRI) - Duncan Research (NASDAQ:APRI)
www.duncanindependent.com - September 27 at 3:34 PM
News IconApricus Biosciences Inc (NASDAQ:APRI) Plunges on Issue of New Shares - Scibility Media (NASDAQ:APRI)
scibilitymedia.com - September 27 at 3:34 PM
investornewswire.com logoExpected For Apricus Biosciences, Inc (NASDAQ:APRI) Sales Of $10.33 - Investor Newswire (NASDAQ:APRI)
www.investornewswire.com - September 27 at 8:01 AM
biz.yahoo.com logoAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity (NASDAQ:APRI)
biz.yahoo.com - September 27 at 8:01 AM
News IconBiotech Companies To Look Out For: Allergan plc (AGN), Apricus Biosciences, Inc. (APRI) - The Independent Republic (NASDAQ:APRI)
theindependentrepublic.com - September 26 at 3:36 PM
News IconInvestor's Alert: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP ... - Newburgh Press (NASDAQ:APRI)
newburghpress.com - September 26 at 3:36 PM
News IconApricus Biosciences Plans to Raise $4.6M in Direct Offering of Common Stock (NASDAQ:APRI)
sdbj.com - September 26 at 8:15 AM
News IconKeen Investors Find News on Apricus Biosciences, Inc. (NASDAQ:APRI) - Duncan Research (NASDAQ:APRI)
www.duncanindependent.com - September 24 at 3:30 PM
investors.com logoApricus Biosciences raises US$4.6mln through share issue - Proactive Investors USA & Canada (NASDAQ:APRI)
www.proactiveinvestors.com - September 24 at 3:30 PM
globenewswire.com logoApricus Biosciences Announces $4.6 Million Registered Direct ... - GlobeNewswire (press release) (NASDAQ:APRI)
globenewswire.com - September 24 at 3:30 PM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences Announces $4.6 Million Registered Direct Offering (NASDAQ:APRI)
www.finanznachrichten.de - September 24 at 8:52 AM
News IconApricus Biosciences Inc. Plans to Raise $4.6M in Direct Offering of Common Stock (NASDAQ:APRI)
www.sdbj.com - September 24 at 8:52 AM
investors.com logoApricus Biosciences raises US$4.6mln through share issue (NASDAQ:APRI)
www.proactiveinvestors.com - September 24 at 8:52 AM
News IconApricus Biosciences Announces $4.6 Million Registered Direct ... - EconoTimes (NASDAQ:APRI)
www.econotimes.com - September 23 at 3:59 PM
News IconUnder the Microscope, Zeroing in at Apricus Biosciences, Inc. (NASDAQ:APRI) - Duncan Research (NASDAQ:APRI)
www.duncanindependent.com - September 23 at 8:23 AM
globenewswire.com logoApricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati - GlobeNewswire (press release) (NASDAQ:APRI)
globenewswire.com - September 23 at 8:23 AM
News IconApricus Biosciences Announces $4.6 Million Registered Direct Offering - Yahoo Sports (NASDAQ:APRI)
sports.yahoo.com - September 23 at 8:23 AM
publicnow.com logoApricus Biosciences Announces $4.6 Million Registered Direct Offering (NASDAQ:APRI)
www.publicnow.com - September 23 at 8:23 AM
globenewswire.com logoApricus Biosciences Announces Completion of Transfer of the Marketing Authorizations for Vitaros® in Finland and ... - GlobeNewswire (press release) (NASDAQ:APRI)
globenewswire.com - September 21 at 4:28 PM
finance.yahoo.com logoApricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati - Yahoo Finance (NASDAQ:APRI)
finance.yahoo.com - September 21 at 4:28 PM
streetinsider.com logoApricus Biosciences (APRI) Announces Launch of Vitaros in Czech Republic (NASDAQ:APRI)
www.streetinsider.com - September 21 at 8:58 AM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati (NASDAQ:APRI)
www.finanznachrichten.de - September 21 at 8:58 AM
reuters.com logoBRIEF-Apricus biosciences announces completion of transfer of marketing authorizations (NASDAQ:APRI)
www.reuters.com - September 21 at 8:58 AM
finance.yahoo.com logo7:03 am Apricus Biosciences announces the launch of Vitaros in the Czech Republic and Slovakia by Recordati (NASDAQ:APRI)
finance.yahoo.com - September 21 at 8:58 AM
publicnow.com logoApricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati (NASDAQ:APRI)
www.publicnow.com - September 21 at 8:58 AM
News IconPenny Stock Investors Take an Interest in Apricus Biosciences, Inc. (NASDAQ:APRI) - Duncan Research (NASDAQ:APRI)
www.duncanindependent.com - September 20 at 3:31 PM
investornewswire.com logoApricus Biosciences, Inc (NASDAQ:APRI)'s Expectation Of $10.33 In Sales - Investor Newswire (NASDAQ:APRI)
www.investornewswire.com - September 20 at 9:26 AM
News IconNoticeable Stock: National Steel Company (NYSE:SID), Apricus Biosciences, Inc (NASDAQ:APRI) - Newburgh Press (NASDAQ:APRI)
newburghpress.com - September 20 at 9:26 AM
nasdaq.com logoApricus Biosciences Announces Completion of Transfer of the Marketing Authorizations for Vitaros® in Finland and ... - Nasdaq (NASDAQ:APRI)
www.nasdaq.com - September 20 at 9:26 AM
publicnow.com logoApricus Biosciences Announces Completion of Transfer of the Marketing Authorizations for Vitaros® in Finland and Denmark to Ferring Pharmaceuticals (NASDAQ:APRI)
www.publicnow.com - September 20 at 9:26 AM
capitalcube.com logoETF’s with exposure to Apricus Biosciences, Inc. : September 16, 2016 (NASDAQ:APRI)
www.capitalcube.com - September 16 at 12:13 PM
rttnews.com logoApricus Bioscienc To Present At Rodman & Renshaw Conference; Webcast At 3:25 PM (NASDAQ:APRI)
www.rttnews.com - September 13 at 3:32 PM
News IconApricus Biosciences, Inc (NASDAQ:APRI) From The Analysts Point of View - National Daily Press (NASDAQ:APRI)
www.nationaldailypress.com - September 9 at 3:32 PM
finance.yahoo.com logoApricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference - Yahoo Finance (NASDAQ:APRI)
finance.yahoo.com - September 9 at 3:32 PM
finance.yahoo.com logoApricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina - Yahoo Finance (NASDAQ:APRI)
finance.yahoo.com - September 9 at 3:32 PM
globenewswire.com logoApricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina - GlobeNewswire (press release) (NASDAQ:APRI)
globenewswire.com - September 8 at 3:31 PM
reuters.com logoBRIEF-Apricus Biosciences announces approval of Vitaros for the treatment of Erectile Dysfunction in Argentina (NASDAQ:APRI)
uk.reuters.com - September 8 at 10:32 AM
publicnow.com logoApricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina (NASDAQ:APRI)
www.publicnow.com - September 8 at 10:32 AM
News IconApricus Biosciences to Present at the Rodman Renshaw 18th Annual Global Investment Conference - EconoTimes (NASDAQ:APRI)
www.econotimes.com - September 7 at 3:32 PM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:APRI)
www.finanznachrichten.de - September 7 at 12:30 PM
reuters.com logoBRIEF-Apricus Biosciences announces launch of novel topical treatment (NASDAQ:APRI)
www.reuters.com - September 7 at 12:30 PM
rttnews.com logoApricus' Partner Recordati Launches Vitaros In Portugal, Ireland And Poland (NASDAQ:APRI)
www.rttnews.com - September 7 at 12:30 PM
finance.yahoo.com logoApricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:APRI)
finance.yahoo.com - September 7 at 12:30 PM
globenewswire.com logoApricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal ... - GlobeNewswire (press release) (NASDAQ:APRI)
globenewswire.com - September 6 at 8:38 PM
News IconApricus Biosciences Announces the Launch of Its Novel Topical ... - P&T Community (NASDAQ:APRI)
ptcommunity.com - September 6 at 3:31 PM
capitalcube.com logoETF’s with exposure to Apricus Biosciences, Inc. : September 6, 2016 (NASDAQ:APRI)
www.capitalcube.com - September 6 at 3:31 PM
investornewswire.com logoApricus Biosciences, Inc (NASDAQ:APRI) Expects Sales Of $10.33 - Investor Newswire (NASDAQ:APRI)
www.investornewswire.com - September 6 at 8:22 AM
News IconApricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal ... - EconoTimes (NASDAQ:APRI)
www.econotimes.com - September 6 at 8:22 AM
finance.yahoo.com logoApricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati (NASDAQ:APRI)
finance.yahoo.com - September 6 at 8:22 AM
News IconHC Stocks Growth- Pfizer Inc. (NYSE:PFE), Apricus Biosciences Inc (NASDAQ:APRI) - share market updates (press release) (NASDAQ:APRI)
sharemarketupdates.com - September 2 at 3:34 PM

Social

Apricus Biosciences (NASDAQ:APRI) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff